4.4 Article

HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses

Journal

AIDS
Volume 24, Issue 8, Pages 1095-1105

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAD.0b013e3283377a1e

Keywords

activation; cellular immunity; HIV; pathogenesis; regulatory T cells

Funding

  1. NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI) [AI-067854]
  2. UCSF/Gladstone Center for AIDS [P30 AI27763]
  3. NIAID [AI069994, AI44595]
  4. UCSF Clinical and Translational Science Institute [UL1 RR024131-01]
  5. American Foundation for AIDS [106710-40-RGRL]

Ask authors/readers for more resources

Objective: HIV+ elite controllers are a unique group of rare individuals who maintain undetectable viral loads in the absence of antiretroviral therapy. We studied immune responses in these individuals to inform vaccine development, with the goal of identifying the immune correlates of protection from HIV. Methods: Wecompared markers of cellular activation, HIV-specific immune responses and regulatory T (Treg) cell frequencies in four groups of individuals: HIV-negative healthy controls, elite controllers (HIV RNA level < 75 copies/ml), individuals on HAART and individuals with HIV RNA level more than 10 000 copies/ ml (noncontrollers). Results: Elite controllers possessed significantly lower levels of activated HIV-specific CD8(+) T cells and of recently divided HIV-specific CD4(+) T cells than noncontrollers, whereas these differences were not seen in the respective cytomegalovirus-specific T-cell populations. Elite controllers also mounted a stronger and broader cytokine and chemokine response following HIV-specific stimulation than individuals on HAART and noncontrollers. Finally, we found that HAART-suppressed individuals had elevated Treg cell frequencies, whereas elite controllers and noncontrollers maintained normal percentages of Treg cells. Conclusion: Elite controllers maintain high levels of HIV-specific immune responses with low levels of HIV-specific T-cell activation and do not have elevated Treg cell levels. Based on these data an ideal HIV vaccine would induce strong HIV-specific immune responses whereas minimizing HIV-specific T-cell activation. (C) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available